Status:
TERMINATED
Cardiotoxic Effects of Chemotherapy in Patients With Sarcomas: A Two and Three-dimensional Echocardiographic Speckle Tracking Imaging Study
Lead Sponsor:
Mayo Clinic
Conditions:
Sarcoma
Eligibility:
All Genders
18+ years
Brief Summary
This study is being done to identify markers that will allow researchers to identify in advance patients with sarcomas who are at highest risk for developing heart failure related to chemotherapy.
Detailed Description
PRIMARY OBJECTIVES: I. To detect acute and subacute changes in myocardial function by two-dimensional (2D)-Speckle Tracking Echocardiography (STE) derived strain and strain rate in sarcoma patients u...
Eligibility Criteria
Inclusion
- Patients followed at Mayo Clinic and treated for sarcoma with doxorubicin as first-line treatment
Exclusion
- First-line treatment not including doxorubicin
- Treatment performed outside of Mayo Clinic with different protocols
- Age \< 18 years
Key Trial Info
Start Date :
January 20 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 9 2024
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT06511388
Start Date
January 20 2016
End Date
October 9 2024
Last Update
October 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905